Good evening :)
$
₹
M

MDxHealth SA ADR

MDXH

NASDAQ
M

MDxHealth SA ADR

MDXH

NASDAQ
$0.590.50% (-0.00)
$
₹
$0.590.50% (-0.00)
High
—
—
Low
—
—
Returns
—
—
1D
1W
1M
1Y
5Y
Max
Loading...
1D
1W
1M
1Y
5Y
Max

Healthcare

Diagnostics & Research

Micro Cap

With a market cap of $60.1M the stock is ranked 5019

Key Metrics

Key Metrics

PE TTM
PE TTM

Close price divided by the earnings per share for the trailing twelve months

—
PB
PB

Close price divided by the book value per share at the end of the most recent quarter

23.63
EPS TTM
EPS TTM

Net profit earned per share over the trailing twelve months (sum of the last 4 quarters)

$-0.71
PEG Ratio
PEG Ratio

Price-to-Earnings (P/E) ratio divided by the forecasted annual earnings per share (EPS) growth rate over the next five years

—
Profit Margin
Profit Margin

Net profit divided by the total revenue for the most recent financial year

-32.74%
Dividend Yield
Dividend Yield

Annual dividend per share for the trailing twelve months divided by the close price

—

Analyst Ratings & Forecast
Analyst Ratings & Forecast

Based on 6 analysts' reports

Buy
6 analysts
Hold
0 analyst
Sell
0 analyst

Analysts expect a +200.00% price upside over the next year

Current Price$0.59
Target Price$1.8

Company Profile

MDxHealth SA, a commercial-stage precision diagnostics company, provides urologic solutions in the United States, Europe, and internationally. The company's testing solutions include Confirm mdx for prostate cancer tissue test that validates epigenetic test that guides the detection of occult prostate cancer on a patient's previously biopsied negative tissue; ExoD, a non-invasive urine test to assess risk of having clinically prostate cancer; and Resolve mdx for urinary tract infection that identifies personalized effective antibiotic options against the patient's infection. It offers genomic prostate score, which provides personalized genomic insights to physicians and patients navigating the complexities of prostate cancer diagnosis and treatment. The company sells its products through urology sales force consisting of direct sales representatives, strategic account managers, and regional sales managers. The company has a collaboration the initiation of Genomic Prostate Score (GPS) testing. The company was formerly known as OncoMethylome Sciences SA and changed its name to MDxHealth SA in October 2010. MDxHealth SA was incorporated in 2003 and is headquartered in Herstal, Belgium.
MDxHealth SA, a commercial-stage precision diagnostics company, provides urologic solutions in the United States, Europe, and internationally. The company's testing solutions include Confirm mdx for prostate cancer tissue test that validates epigenetic test that guides the detection of occult prostate cancer on a patient's previously biopsied negative tissue; ExoD, a non-invasive urine test to assess risk of having clinically prostate cancer; and Resolve mdx for urinary tract infection that identifies personalized effective antibiotic options against the patient's infection. It offers genomic prostate score, which provides personalized genomic insights to physicians and patients navigating the complexities of prostate cancer diagnosis and treatment. The company sells its products through urology sales force consisting of direct sales representatives, strategic account managers, and regional sales managers. The company has a collaboration the initiation of Genomic Prostate Score (GPS) testing. The company was formerly known as OncoMethylome Sciences SA and changed its name to MDxHealth SA in October 2010. MDxHealth SA was incorporated in 2003 and is headquartered in Herstal, Belgium.

Peers

Peers

AbbVie Inc
ABBV
AbbVie Inc
P/E Ratio
74.56
74.56
1Y Return
19.44%
19.44%
Buy Reco %
57.14
57.14
Amgen Inc
AMGN
Amgen Inc
P/E Ratio
23.98
23.98
1Y Return
38.44%
38.44%
Buy Reco %
46.87
46.87
Gilead Sciences Inc
GILD
Gilead Sciences Inc
P/E Ratio
—
—
1Y Return
33.84%
33.84%
Buy Reco %
63.33
63.33
Vertex Pharmaceuticals Inc
VRTX
Vertex Pharmaceuticals Inc
P/E Ratio
29.58
29.58
1Y Return
33.3%
33.3%
Buy Reco %
52.94
52.94
Regeneron Pharmaceuticals Inc
REGN
Regeneron Pharmaceuticals Inc
P/E Ratio
19.41
19.41
1Y Return
34.16%
34.16%
Buy Reco %
76.00
76.00

Peers & Comparison

Peers & Comparison

Comparing 2 stocks from
HealthcareDiagnostics & Research

Valuation

Returns

Forecast

StockPE TTMPE TTMPBPBPEG RatioPEG Ratio
MDxHealth SA ADR -23.63-
AbbVie Inc74.5650.450.54
Amgen Inc23.9817.832.32

Price Comparison

Price Comparison

1 Month

1 Year

5 Years

Loading...

Financials

Financials

Income

Balance Sheet

Cash Flow

27.4
-8
54.6
-18.7
54.6
-18.7
27.2
-11.5
Q3 2025
Q4 2025
Q1 2026
Q2 2026
Revenue
Net Income
Financial YearQ1 2024Q2 2024Q3 2024Q4 2024Q1 2025Q2 2025Q3 2025Q4 2025Q1 2026Q2 2026
Total Revenue19.8341.9923.3148.0524.2926.6027.4354.6654.6627.20
Net Income-8.51-20.03-11.18-18.03-9.20-7.37-8.01-18.77-18.77-11.53
Net Profit Margin-42.91%-47.71%-47.98%-37.51%-37.90%-27.70%-29.19%-34.34%-34.34%-42.38%
See CostsAll values in $ Million

Frequently asked questions

  1. MDxHealth SA ADR (MDXH) share price today is $0.59 as of September 22, 2026 at 10:23 PM IST. The stock touched a day high of $0.63 and a day low of $0.59.

  2. MDxHealth SA ADR stock trades on NASDAQ under the ticker symbol MDXH.

  3. MDxHealth SA ADR's market capitalization is $60.11M as of September 22, 2026 at 10:23 PM IST.

  4. MDxHealth SA ADR's price-to-earnings (P/E) ratio is N/A as of September 22, 2026.

  5. MDxHealth SA ADR's price-to-book (P/B) ratio is 23.63 as of September 22, 2026.

  6. Yes, You can buy MDxHealth SA ADR shares from India through Tickertape, via our partnership with ViewTrade IFSC under the IFSCA Global Access framework, subject to RBI’s Liberalised Remittance Scheme (LRS) limits.

  7. Indian investors can buy MDxHealth SA ADR shares in three steps: 1. Search MDxHealth SA ADR on the Tickertape app and tap Invest. 2. Complete your one-time digital KYC. 3. Fund your account and buy from as low as $1 via fractional shares.

  8. Since MDxHealth SA ADR trades in USD, an Indian investor's INR returns depend on both the stock's price movement and the USD-INR exchange rate. If the rupee depreciates against the dollar, INR returns are boosted beyond the stock's USD return; if the rupee appreciates, INR returns are reduced.

  9. Indian investors can start investing in MDxHealth SA ADR (MDXH) shares from as little as $1 through fractional ownership on Tickertape - for example, $10 buys approximately 16.7504 shares at the current price of $0.59.

Loading...